TMS for Adolescents and Young Adults: A Family Guide
- Food and Drug Administration cleared Transcranial Magnetic Stimulation (TMS) for adolescents aged 15 and older in April 2024, marking the first time a non-drug brain stimulation therapy has...
- TMS is a noninvasive procedure that uses gentle magnetic pulses to stimulate underactive regions of the brain.
- Data from the largest study of its kind indicates that 70% of teenagers experienced meaningful improvement in their depression symptoms following TMS treatment, while less than 1% of...
The U.S. Food and Drug Administration cleared Transcranial Magnetic Stimulation (TMS) for adolescents aged 15 and older in April 2024, marking the first time a non-drug brain stimulation therapy has been approved for the treatment of teen depression.
TMS is a noninvasive procedure that uses gentle magnetic pulses to stimulate underactive regions of the brain. Specifically, the technology targets the dorsolateral prefrontal cortex, an area linked to mood regulation, to encourage healthy neural activity and reset brain circuits involved in mood control.
Clinical Outcomes and Safety Profile
Data from the largest study of its kind indicates that 70% of teenagers experienced meaningful improvement in their depression symptoms following TMS treatment, while less than 1% of participants experienced a worsening of symptoms.
A study published in JAACAP Open on July 1, 2025, further validated these results, finding that outcomes for adolescent and young adult groups mirrored those reported in large adult registry samples.
From a safety perspective, TMS does not carry a black box warning
for increased suicidal thoughts or behaviors, a distinction that separates it from many antidepressant medications.
Technical Implementation and Patient Experience
The treatment process involves placing a small device against the scalp to deliver targeted pulses. Sessions typically last between 20 and 40 minutes and do not require sedation or anesthesia.
Because the procedure is noninvasive and does not involve systemic drug exposure, patients can return to school, sports, or other social activities immediately after their sessions.
Technological advancements in the field have introduced fMRI-guided targeting and accelerated protocols. These innovations are designed to improve the accuracy of the stimulation and compress treatment timelines, which is particularly relevant for developing adolescent brains.
Regulatory and Insurance Status
In addition to standard TMS, the FDA has also cleared Deep Transcranial Magnetic Stimulation for adolescents diagnosed with Major Depressive Disorder (MDD).
Access to the therapy has expanded through insurance coverage. Major providers, including Cigna, Aetna, Humana, and multiple BlueCross BlueShield plans, now cover TMS for adolescent patients.
- FDA clearance for adolescents (ages 15-21) occurred in April 2024.
- Treatment targets the dorsolateral prefrontal cortex.
- 70% of teens in a major study showed meaningful improvement.
- No anesthesia or sedation is required for the 20-to-40-minute sessions.